Jyothy Labs hits 52-week low: key FY25 numbers

Stock sinks to a fresh 52-week low

Jyothy Labs Ltd. shares slid to Rs 200.45, marking a sharp 49.9% fall from the 52-week high of Rs 399.95. The move came amid a broader sell-off, with the FMCG sector down 2.07% on the day and the Sensex falling 2.41% after a gap-down opening. The scale of the decline meant the stock underperformed the broader sector move highlighted in the data. The drop also extended a weak phase for the counter relative to the BSE500 index across one year, three years, and the last three months, as cited. While the price action was the headline, the underlying financial picture remained mixed, with steady long-term growth rates but softer recent quarters. That contrast between price momentum and business metrics sits at the centre of the current debate around the stock.

What the tape showed across exchanges

Exchange snapshots in the data show the stock trading around the Rs 240 level on February 20, with BSE indicating a previous close of Rs 240.70 and an open of Rs 240.00. NSE data showed a previous close of Rs 239.93 and an open of Rs 239.90 around the same time window. These levels sit well above the cited 52-week low of Rs 200.45, underlining how quickly sentiment and prices have shifted across different sessions. The broader context in the article points to sustained selling pressure rather than a single isolated trade. With sector and index moves both negative, the decline was not occurring in a vacuum, but the magnitude of Jyothy Labs’ fall stood out.

Five-year growth looks steady, but the latest quarter was soft

Over the last five years, Jyothy Labs delivered modest growth, with net sales rising at an annualised 10.20% and operating profit increasing at 14.04%. However, the latest quarterly commentary in the data flagged subdued performance, with profits falling 7.3% year-on-year and EPS at Rs 2.08 for the latest quarter. That combination suggests the company has not converted longer-term brand and distribution strength into consistent quarterly earnings momentum recently. The article text also references “flat results” reported in March 2025, tying the soft patch to the most recent reported period.

Q4 FY25: profit dips, revenue edges up

For the quarter ended March 31, 2025 (Q4 FY25), Jyothy Labs reported consolidated net profit of Rs 76.27 crore, down 2.4% from Rs 78.15 crore in Q4 FY24. Revenue from operations increased about 1% to Rs 666.96 crore from Rs 659.99 crore a year earlier. The company also reported that consolidated revenue for the quarter was about Rs 667 crore, with value growth of 1.1% and volume growth of 4% year-on-year. EBITDA margin improved to 16.8% from 16.4% in Q4 FY24, indicating margin resilience even as profit slipped. The numbers point to cost pressures weighing on the bottom line despite stable topline growth.

Costs, depreciation, and an exceptional loss

Cost inflation was visible in raw material consumption, which rose to Rs 311.71 crore from Rs 295.63 crore in Q4 FY24. Depreciation and amortisation increased 13.14% to Rs 14.55 crore from Rs 12.86 crore. Total expenses in Q4 were Rs 571.23 crore, slightly higher than Rs 565.73 crore a year ago. The company also booked an exceptional loss of Rs 4.30 crore on a consolidated basis linked to the sale of its entire stake in Jyothy Kallol Bangladesh Limited for Rs 2.10 crore. These line items help explain why profit did not track the modest revenue increase.

FY25 snapshot: revenue growth, margins improve slightly

For FY25, the company reported net profit of Rs 370.38 crore, marginally higher than Rs 369.30 crore in FY24. Total consolidated income rose 3.26% to Rs 2,902.56 crore, supported by 6.4% volume growth. Gross margin improved by 100 basis points to 50.1% compared with the previous year. Operating EBITDA margin for FY2025 was 17.5%, up 10 basis points year-on-year, as per the earnings statement. The data also separately cites FY25 revenue at Rs 2,847 crore and EBITDA at Rs 499.6 crore, with the margin at 17.5% and net profit at Rs 370.4 crore, reinforcing the broadly steady full-year picture.

Liquidity and efficiency signals: mixed indicators

Despite the sell-off, the company is described as showing strong management efficiency, reflected in a ROE of 16.06%. On liquidity, the dataset contains two different cash indicators: one section cites cash and cash equivalents shrinking to Rs 142.35 crore, while another states the company held Rs 757 crore in cash reserves as of March 31, 2025 and describes it as debt-free. The same dataset flags a low debtors turnover ratio of 10.37 times, suggesting slower collections relative to prior expectations. These mixed signals complicate a simple narrative of either stress or comfort, and they are part of why the market response has stayed cautious.

Key numbers at a glance

Latest earnings datapoint (FY25-26) in the dataset

The data also lists a “Last Earnings Date” of Q0 FY25-26 on February 9, 2026, with revenue at Rs 739 crore. It shows gross profit of Rs 95 crore and net profit of Rs 81 crore for that period, alongside sequential declines in gross profit and net profit. This section reinforces the article’s broader point that near-term profitability trends have been softer than the longer-term growth rates. With EPS also described as low at Rs 2.08 in the latest quarter, near-term earnings delivery remains the key operational variable investors appear to be tracking.

Market impact and what investors are weighing

The dataset frames the 52-week low as the result of subdued recent earnings, weaker liquidity indicators, and negative technical momentum. At the same time, it lists counterpoints that typically matter for long-only investors: a respectable ROE, low leverage, and significant institutional ownership. The Q4 and FY25 numbers show that margins held up and volume grew, but cost pressures and below-expectation operating signals such as debtor turnover created a tougher narrative. With the stock also underperforming the BSE500 over multiple horizons, the market has demanded clearer evidence of consistent earnings improvement.

Conclusion

Jyothy Labs’ fall to Rs 200.45 and the near-50% drop from its 52-week high has put its quarterly execution under scrutiny. FY25 results showed modest revenue growth, stable-to-improving margins, and largely flat full-year profit, even as Q4 profit dipped and costs rose. The next set of reported financial updates and management commentary will be critical for investors assessing whether the stock’s weak momentum is driven by temporary pressures or a more persistent slowdown.